225 related articles for article (PubMed ID: 16289523)
1. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
[TBL] [Abstract][Full Text] [Related]
2. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
3. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
Strauss SM; Astone JM; Jarlais DD; Hagan H
Drug Alcohol Depend; 2004 Mar; 73(3):227-36. PubMed ID: 15036545
[TBL] [Abstract][Full Text] [Related]
4. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection.
Hagan H; Strauss SM; Astone JM; Des Jarlais DC
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S297-303. PubMed ID: 15768338
[TBL] [Abstract][Full Text] [Related]
5. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility.
Tyndall MW; Kerr T; Zhang R; King E; Montaner JG; Wood E
Drug Alcohol Depend; 2006 Jul; 83(3):193-8. PubMed ID: 16356659
[TBL] [Abstract][Full Text] [Related]
6. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
[TBL] [Abstract][Full Text] [Related]
7. Organizational and client determinants of cost in outpatient substance abuse treatment.
Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
[TBL] [Abstract][Full Text] [Related]
8. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
9. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.
Grebely J; Genoway KA; Raffa JD; Dhadwal G; Rajan T; Showler G; Kalousek K; Duncan F; Tyndall MW; Fraser C; Conway B; Fischer B
Drug Alcohol Depend; 2008 Jan; 93(1-2):141-7. PubMed ID: 17997050
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment.
Gonzales R; Marinelli-Casey P; Shoptaw S; Ang A; Rawson RA
J Subst Abuse Treat; 2006 Sep; 31(2):195-202. PubMed ID: 16919748
[TBL] [Abstract][Full Text] [Related]
11. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV.
Kresina TF; Bruce RD; Cargill VA; Cheever LW
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S83-8. PubMed ID: 16265621
[TBL] [Abstract][Full Text] [Related]
12. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
Litwin AH; Soloway I; Gourevitch MN
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
[TBL] [Abstract][Full Text] [Related]
13. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services.
Astone JM; Strauss SM; Hagan H; Des Jarlais DC
Am J Drug Alcohol Abuse; 2004 Nov; 30(4):783-97. PubMed ID: 15624549
[TBL] [Abstract][Full Text] [Related]
14. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
[TBL] [Abstract][Full Text] [Related]
15. Ryan White CARE Act Title IV programs: a preliminary characterization of benefits and costs.
Abramowitz S; Greene D
AIDS Public Policy J; 2005; 20(3-4):108-25. PubMed ID: 17624034
[TBL] [Abstract][Full Text] [Related]
16. Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States of America.
Friedman SR; Tempalski B; Brady JE; Friedman JJ; Cooper HL; Flom PL; McGrath MM; Gostnell K; Des Jarlais DC
Int J Drug Policy; 2007 Dec; 18(6):475-85. PubMed ID: 18061873
[TBL] [Abstract][Full Text] [Related]
17. Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview.
Bobrova N; Sarang A; Stuikyte R; Lezhentsev K
Int J Drug Policy; 2007 Aug; 18(4):313-8. PubMed ID: 17689380
[TBL] [Abstract][Full Text] [Related]
18. Determinants of hospital-based substance abuse treatment programs.
Bell R
Hosp Health Serv Adm; 1994; 39(1):93-102. PubMed ID: 10132103
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
20. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia.
Krupitsky EM; Zvartau EE; Lioznov DA; Tsoy MV; Egorova VY; Belyaeva TV; Antonova TV; Brazhenko NA; Zagdyn ZM; Verbitskaya EV; Zorina Y; Karandashova GF; Slavina TY; Grinenko AY; Samet JH; Woody GE
Eur Addict Res; 2006; 12(1):12-9. PubMed ID: 16352898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
